160 related articles for article (PubMed ID: 12709332)
41. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
Weller TM; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
[TBL] [Abstract][Full Text] [Related]
42. In vivo efficacy of a new quinolone, DQ-113, against Streptococcus pneumoniae in a mouse model.
Otsu Y; Yanagihara K; Fukuda Y; Miyazaki Y; Tsukamoto K; Hirakata Y; Tomono K; Kadota J; Tashiro T; Murata I; Kohno S
Antimicrob Agents Chemother; 2003 Dec; 47(12):3699-703. PubMed ID: 14638468
[TBL] [Abstract][Full Text] [Related]
43. Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.
Abdelraouf K; Nicolau DP
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799200
[TBL] [Abstract][Full Text] [Related]
44. Antimicrobial activity of DW286 against Streptococcus pneumoniae.
Park HS; Jung SJ; Choi DR; Kwak JH
Int J Antimicrob Agents; 2010 Sep; 36(3):230-3. PubMed ID: 20627463
[TBL] [Abstract][Full Text] [Related]
45. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
Nicolau DP; Ambrose PG
Am J Med; 2001 Dec; 111 Suppl 9A():13S-18S; discussion 36S-38S. PubMed ID: 11755438
[TBL] [Abstract][Full Text] [Related]
46. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
Gales A; Sader H; Jones RN;
Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
[TBL] [Abstract][Full Text] [Related]
47. Activities of garenoxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.
Azoulay-Dupuis E; Bédos JP; Mohler J; Peytavin G; Isturiz R; Moine P; Rieux V; Cherbuliez C; Péchère JC; Fantin B; Köhler T
Antimicrob Agents Chemother; 2004 Mar; 48(3):765-73. PubMed ID: 14982762
[TBL] [Abstract][Full Text] [Related]
48. Application of fluoroquinolone pharmacodynamics.
Wright DH; Brown GH; Peterson ML; Rotschafer JC
J Antimicrob Chemother; 2000 Nov; 46(5):669-83. PubMed ID: 11062185
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
Takahata M; Shimakura M; Hori R; Kizawa K; Todo Y; Minami S; Watanabe Y; Narita H
Antimicrob Agents Chemother; 2001 Jan; 45(1):312-5. PubMed ID: 11120986
[TBL] [Abstract][Full Text] [Related]
50. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
Fukuda Y; Takahata M; Mitsuyama J
J Infect Chemother; 2006 Feb; 12(1):1-8. PubMed ID: 16506083
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Bédos JP; Rieux V; Bauchet J; Muffat-Joly M; Carbon C; Azoulay-Dupuis E
Antimicrob Agents Chemother; 1998 Apr; 42(4):862-7. PubMed ID: 9559797
[TBL] [Abstract][Full Text] [Related]
52. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.
Ambrose PG; Grasela DM; Grasela TH; Passarell J; Mayer HB; Pierce PF
Antimicrob Agents Chemother; 2001 Oct; 45(10):2793-7. PubMed ID: 11557471
[TBL] [Abstract][Full Text] [Related]
53. Penicillin pharmacodynamics in four experimental pneumococcal infection models.
Erlendsdottir H; Knudsen JD; Odenholt I; Cars O; Espersen F; Frimodt-Møller N; Fuursted K; Kristinsson KG; Gudmundsson S
Antimicrob Agents Chemother; 2001 Apr; 45(4):1078-85. PubMed ID: 11257018
[TBL] [Abstract][Full Text] [Related]
54. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.
Knudsen JD; Fuursted K; Raber S; Espersen F; Frimodt-Moller N
Antimicrob Agents Chemother; 2000 May; 44(5):1247-54. PubMed ID: 10770759
[TBL] [Abstract][Full Text] [Related]
55. Antipneumococcal activity of BMS 284756 compared to those of six other agents.
Pankuch GA; Nagai K; Davies TA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2002 Jan; 46(1):251-4. PubMed ID: 11751147
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
[TBL] [Abstract][Full Text] [Related]
57. In vivo pharmacodynamics of new lipopeptide MX-2401.
Craig WA; Andes DR; Stamstad T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5092-8. PubMed ID: 20855736
[TBL] [Abstract][Full Text] [Related]
58.
Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987156
[TBL] [Abstract][Full Text] [Related]
59. Pharmacodynamic profiling of modithromycin: assessment in a pneumococcal murine pneumonia model.
Maglio D; Sun HK; Patel T; Banevicius MA; Nightingale CH; Arya A; Wang G; Chen Z; Phan LT; Nicolau DP
Int J Antimicrob Agents; 2014 Jun; 43(6):540-6. PubMed ID: 24703590
[TBL] [Abstract][Full Text] [Related]
60. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
